Cardiac Effects of Adding Electrolytes and Oxygen to Iohexol in a Dog Model of Contrast Media-Induced Ventricular Fibrillation

We investigated whether addition of a balanced electrolyte supplement and oxygen to the nonionic contrast medium iohexol reduces the risk of ventricular fibrillation (VF), and studied regional electrophysiology prior to the VF event. Twenty ml of each test solution were infused at a rate of 0.5 ml/s into the left anterior descending coronary artery (LAD) in 8 anesthetized dogs. LAD was externally occluded during infusion, to simulate a wedged catheter situation. ECG, hemodynamics, regional epicardial monophasic action potential duration (MAPD) and ventricular activation times (VAT) were calculated. All infusions with iohexol caused VF within 27 s. Five of 12 infusions with iohexol + 30 mmol NaCl, 3 of 11 infusions with iohexol + electrolytes (IPE) (NaCl, KCl, CaCl2 and MgCl2) and 4 of 11 infusions with IPE with oxygen addition (IPE + O2) caused VF after 45 s. Iohexol did not change MAPD prior to the VF event. Iohexol + 30 mmol NaCl and the IPE solutions lengthened MAPD initially, but at the time of the VF event MAPD were normalized or shortened. We conclude that electrolyte supplement to iohexol may prevent VF, probably by lengthening MAPD.

Iodixanol in Cardioangiography in Patients with Coronary Artery Disease

Iodixanol is a new nonionic, dimeric contrast medium. With the addition of 18 mmol/l Na+ and 0.3 mmol/l Ca++ to iodixanol 320 mg I/ml a plasma-isotonic solution was obtained. The purpose was to evaluate the suitability of iodixanol for use in cardioangiography by determining the diagnostic efficacy, patient tolerability, and cardiac and renal side-effects. Initially, 14 patients with coronary artery disease were examined using iodixanol. A double-blind, randomized study was then performed in 72 patients, comparing iodixanol and iohexol. Serum and urine were sampled before the examination, and one and 2 days after. The diagnostic information was good and the number of adverse events low with iodixanol. The patients reported significantly less of a sensation of warmth following injection of iodixanol than iohexol. Our results also indicate that iodixanol 320 mg I/ml influences renal function to a lesser degree than does iohexol 350 mg I/ml. We therefore conclude that isotonic iodixanol is a safe contrast medium for use in cardioangiography.

Sodium Addition and/or Oxygen Saturation of Iohexol during Normal and Reduced Perfusion Pressure

The influence on contractile force (CF) and the propensity for ventricular fibrillation (VF) from infusing the non-ionic contrast medium iohexol during normal (75 cm H2O) and reduced perfusion pressure (35 cm H2O) were investigated in the isolated rabbit heart. Both during normal and reduced perfusion pressure iohexol (150 mg I/ml) with oxygen saturation caused a smaller reduction of CF than iohexol without oxygen. During reduced pressure iohexol with sodium addition (28 mM NaCl) caused less depression of CF than iohexol without sodium. The combination of sodium addition and oxygen saturation had the least influence on CF. Iohexol (350 mg I/ml) without sodium had a similar fibrillatory propensity during both normal and reduced pressure. Enriching iohexol with 28 mM NaCl decreased the risk of VF. The decrease was similar during both normal and reduced pressure. The risk of VF from oxygen saturation of iohexol (350 mg I/ml, without sodium) was similar during both normal and reduced pressure. It is concluded that a small addition of sodium and/or oxygen saturation of a non-ionic monomeric contrast medium have beneficial effects on the heart both during normal perfusion pressure and during ischemia.

Effect on Cardiac Contractile Force from Addition of Cations and Oxygen to Iohexol

The coronary arteries of the isolated rabbit heart were perfused with different contrast media (CM). The effects on cardiac contractile force (CF) from enriching iohexol solutions with sodium, calcium, potassium, magnesium and oxygen were investigated. The effects were studied during normal and reduced perfusion pressure; the latter was intended to simulate flow conditions distal to proximal stenotic processes of the coronary arteries. By adding the above mentioned cations to iohexol (175 mg I/ml) the smallest influence on CF was found when the CM contained 30 mM NaCl, 0.3 mM CaCl2, 0.9 mM KCl and 0.3 mM MgCl2 and this influence on CF was significantly less than caused by iohexol with 30 mM NaCl (p ≤ 0.01). The influence on CF was further reduced when this iohexol solution was oxygenated with 100% oxygen (p ≤ 0.001). This modified iohexol solution caused a significantly smaller influence on CF than the low-osmotic media iohexol, iopamiro, ioversol and ioxaglate (p ≤ 0.001). Ioxaglate caused the greatest decrease in CF of all the CM (p ≤ 0.001) and to a greater extent during reduced flow than during normal flow (p ≤ 0.01). In conclusion, iohexol enriched with a balanced electrolyte solution and saturated with oxygen had a smaller adverse effect on contractility than iohexol, iopamidol, ioversol and ioxaglate.

Computer-assisted continuous ST-segment analysis for clinical research: methodological issues

Continuous ST-segment monitoring has been used to detect acute myocardial ischemia, determine the success of the reperfusion therapy, and predict outcomes in both research and a variety of clinical settings. However, analyzing the abundant electrocardiography (ECG) data recorded using continuous multilead ST-segment monitoring techniques is time consuming and requires expertise. Experienced data interpreters in dedicated ECG core laboratories handle many continuous ECG data records from large clinical trials. Little information on measurement issues for computer-assisted ST-segment analysis is available for individual investigators. Unsupervised or inexperienced computer analysis of ST-segment deviations can, under certain circumstances, yield invalid or unreliable summary indices. The goal of this article is to discuss basic ST-segment measurement principles in evaluating acute myocardial ischemia and methodological issues surrounding the use of computer-assisted ST-segment analysis for continuous ECG data. Variables affecting ST-segment measurements will be examined. Sources and examples of variability for these potential errors will be identified.